• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与头颈部鳞状细胞癌相关的炎症诱导髓源性抑制细胞。

Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck.

作者信息

Chen Wen-Cheng, Lai Chia-Hsuan, Chuang Huei-Chieh, Lin Paul-Yang, Chen Miao-Fen

机构信息

Department of Radiation Oncology, Chang Gung Memorial Hospital at Chiayi, Taiwan.

Chang Gung University, College of Medicine, Taiwan.

出版信息

Head Neck. 2017 Feb;39(2):347-355. doi: 10.1002/hed.24595. Epub 2016 Oct 3.

DOI:10.1002/hed.24595
PMID:27696591
Abstract

BACKGROUND

The purpose of this study was to present our assessment of the significance of myeloid-derived suppressor cells (MDSCs) in head and neck squamous cell carcinoma (HNSCC).

METHODS

We examined the percentage of MDSCs in the peripheral blood of patients with HNSCC. The relationship among MDSC recruitment, tumor progression, and cyclooxygenase (COX)-2 inhibition was also evaluated by animal models.

RESULTS

Circulating MDSCs were significantly increased in patients with HNSCC compared with healthy people, and this was associated with the clinical tumor burden. In immunocompetent 4-nitroquinoline-1-oxide (4-NQO)-induced oral tumor and immunocompromised tumor implantation animal models, MDSC recruitment was associated with the duration of 4-NQO treatment and tumor progression. The responsible mechanisms included the suppressive ability of T-cell proliferation and augmenting angiogenesis by MDSC. Blockade of COX-2 attenuated the induction and function of MDSCs and subsequently inhibited tumor growth.

CONCLUSION

The levels of MDSC are linked with tumor progression in HNSCC. Moreover, targeting COX-2 could be a promising strategy for the treatment of HNSCC. © 2016 Wiley Periodicals, Inc. Head Neck 39: 347-355, 2017.

摘要

背景

本研究旨在阐述我们对髓系来源抑制细胞(MDSCs)在头颈部鳞状细胞癌(HNSCC)中的意义评估。

方法

我们检测了HNSCC患者外周血中MDSCs的百分比。还通过动物模型评估了MDSC募集、肿瘤进展与环氧合酶(COX)-2抑制之间的关系。

结果

与健康人相比,HNSCC患者循环中的MDSCs显著增加,且这与临床肿瘤负荷相关。在免疫活性4-硝基喹啉-1-氧化物(4-NQO)诱导的口腔肿瘤和免疫缺陷肿瘤植入动物模型中,MDSC募集与4-NQO治疗持续时间及肿瘤进展相关。相关机制包括MDSC对T细胞增殖的抑制能力及促进血管生成。COX-2阻断可减弱MDSCs的诱导和功能,进而抑制肿瘤生长。

结论

MDSC水平与HNSCC中的肿瘤进展相关。此外,靶向COX-2可能是治疗HNSCC的一种有前景的策略。© 2016威利期刊公司。《头颈》39: 347 - 355, 2017。

相似文献

1
Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck.与头颈部鳞状细胞癌相关的炎症诱导髓源性抑制细胞。
Head Neck. 2017 Feb;39(2):347-355. doi: 10.1002/hed.24595. Epub 2016 Oct 3.
2
Inhibition of JAK2/STAT3 reduces tumor-induced angiogenesis and myeloid-derived suppressor cells in head and neck cancer.抑制 JAK2/STAT3 减少头颈部癌症中的肿瘤诱导的血管生成和髓系来源的抑制细胞。
Mol Carcinog. 2018 Mar;57(3):429-439. doi: 10.1002/mc.22767. Epub 2017 Dec 30.
3
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.抑制 MDSC 迁移:一种 CXCR1/2 抑制剂,增强头颈部癌症模型中的 NK 细胞免疫治疗。
Clin Cancer Res. 2020 Mar 15;26(6):1420-1431. doi: 10.1158/1078-0432.CCR-19-2625. Epub 2019 Dec 17.
4
LncRNAs as an intermediate in HPV16 promoting myeloid-derived suppressor cell recruitment of head and neck squamous cell carcinoma.长链非编码RNA作为人乳头瘤病毒16型促进头颈部鳞状细胞癌髓源性抑制细胞招募过程中的一种中间介质。
Oncotarget. 2017 Jun 27;8(26):42061-42075. doi: 10.18632/oncotarget.14939.
5
Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma.PMN-髓系来源的抑制细胞的扩增及其在口腔鳞状细胞癌患者中的临床相关性。
Oral Oncol. 2019 Aug;95:157-163. doi: 10.1016/j.oraloncology.2019.06.004. Epub 2019 Jun 22.
6
Host derived macrophage migration inhibitory factor expression attenuates anti-tumoral immune cell accumulation and promotes immunosuppression in the tumor microenvironment of head and neck squamous cell carcinoma.宿主来源的巨噬细胞迁移抑制因子表达减弱了头颈部鳞状细胞癌肿瘤微环境中抗肿瘤免疫细胞的积累,并促进了免疫抑制。
Biochim Biophys Acta Mol Basis Dis. 2024 Oct;1870(7):167345. doi: 10.1016/j.bbadis.2024.167345. Epub 2024 Jul 9.
7
Myeloid-derived suppressor cells in head and neck squamous cell carcinoma.头颈部鳞状细胞癌中的髓源性抑制细胞
Int Rev Cell Mol Biol. 2023;375:33-92. doi: 10.1016/bs.ircmb.2022.11.002. Epub 2023 Jan 11.
8
Blockade of adenosine A2A receptor enhances CD8 T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma.腺苷A2A受体阻断增强头颈部鳞状细胞癌中CD8 T细胞反应并减少调节性T细胞
Mol Cancer. 2017 Jun 7;16(1):99. doi: 10.1186/s12943-017-0665-0.
9
CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.CD244 是头颈部鳞状细胞癌的一个新的治疗靶点。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000245.
10
Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.人头颈鳞状细胞癌相关的信号素4D诱导髓源性抑制细胞扩增。
J Immunol. 2016 Feb 1;196(3):1419-29. doi: 10.4049/jimmunol.1501293. Epub 2016 Jan 6.

引用本文的文献

1
Immunotherapy in Head and Neck Cancer.头颈部癌症的免疫疗法
Cancer Treat Res. 2025;129:119-156. doi: 10.1007/978-3-031-97242-3_7.
2
Immunotherapeutic strategies in head and neck cancer: challenges and opportunities.头颈部癌的免疫治疗策略:挑战与机遇
J Clin Invest. 2025 Apr 15;135(8). doi: 10.1172/JCI188128.
3
Circulating M-MDSC Levels as an Assessment Marker for Post-Treatment Tumor Progression in Recurrent HNC Patients Following Radiation Therapy: A Case Series.循环M-MDSC水平作为复发性头颈部癌患者放疗后治疗后肿瘤进展的评估标志物:病例系列
J Clin Med. 2024 Aug 29;13(17):5130. doi: 10.3390/jcm13175130.
4
The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer.化疗药物的双重生活:吉西他滨在癌症中的免疫调节功能。
Cancer Med. 2024 May;13(10):e7287. doi: 10.1002/cam4.7287.
5
Targeting M-MDSCs enhances the therapeutic effect of BNCT in the 4-NQO-induced murine head and neck squamous cell carcinoma model.靶向髓系来源的抑制性细胞(M-MDSCs)可增强硼中子俘获疗法(BNCT)在4-硝基喹啉-1-氧化物(4-NQO)诱导的小鼠头颈鳞状细胞癌模型中的治疗效果。
Front Oncol. 2023 Oct 2;13:1263873. doi: 10.3389/fonc.2023.1263873. eCollection 2023.
6
Targeted therapy for head and neck squamous cell carcinoma microenvironment.头颈部鳞状细胞癌微环境的靶向治疗
Front Med (Lausanne). 2023 Aug 30;10:1257898. doi: 10.3389/fmed.2023.1257898. eCollection 2023.
7
The Role of IL-17 in the Pathogenesis of Oral Squamous Cell Carcinoma.IL-17 在口腔鳞状细胞癌发病机制中的作用。
Int J Mol Sci. 2023 Jun 8;24(12):9874. doi: 10.3390/ijms24129874.
8
Targeting oral tumor microenvironment for effective therapy.靶向口腔肿瘤微环境以实现有效治疗。
Cancer Cell Int. 2023 May 23;23(1):101. doi: 10.1186/s12935-023-02943-5.
9
promotes tumor progression in oral squamous cell carcinoma.促进口腔鳞状细胞癌的肿瘤进展。
J Cancer. 2022 Sep 21;13(12):3358-3367. doi: 10.7150/jca.73310. eCollection 2022.
10
Mouse Models for Immune Checkpoint Blockade Therapeutic Research in Oral Cancer.口腔癌免疫检查点阻断治疗研究的小鼠模型。
Int J Mol Sci. 2022 Aug 16;23(16):9195. doi: 10.3390/ijms23169195.